N. Anagnostopoulos

发表

Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients

Nikolaos Laoutaris, E. Terpos, X. Yataganas, 2002, British journal of haematology.

Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria

S. Jhanwar, H. Thaler, K. Nafa, 2001, British journal of haematology.

Absolute quantification of the alleles in somatic point mutations by bioluminometric methods based on competitive polymerase chain reaction in the presence of a locked nucleic acid blocker or an allele-specific primer.

T. K. Christopoulos, J. Traeger-Synodinos, E. Kanavakis, 2011, Analytical chemistry.

Serum Hyaluronic Acid Levels Are Altered in Acute Leukemia Patients: Potential Prognostic Implications

N. Sitaras, M. Papastamataki, A. Kotsiou, 2017, Acta Haematologica.

“Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group

E. Hatzimichael, M. Kyrtsonis, A. Symeonidis, 2013, Annals of Hematology.

Treatment of Waldenström's macroglobulinemia with rituximab.

M. Dimopoulos, D. Gika, N. Viniou, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.

M. Dimopoulos, E. Efstathiou, D. Gika, 2002, Clinical lymphoma.

High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents

M. Dimopoulos, T. Economopoulos, A. Symeonidis, 2010, European journal of haematology.

Multiple myeloma in elderly patients: prognostic factors and outcome

M. Dimopoulos, K. Zervas, D. Gika, 2005, European journal of haematology.

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

M. Dimopoulos, D. Heath, P. Croucher, 2008, Leukemia.

Dose Dependent Long-term In Vivo Remission of AML1/ETO Positive Acute Myeloid Leukemia with G-CSF

N. Anagnostopoulos, A. Zomas, M. Fisfis, 2004, Hematology.

Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group.

M. Angelopoulou, F. Kontopidou, D. Rontogianni, 2010, Leukemia research.

Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response

S. Akel, E. Terpos, D. Loukopoulos, 2002, Annals of Hematology.

Leukemic transformation in patients with myelodysplastic syndromes after treatment with granulocyte colony-stimulating factor

G. Pangalis, S. Sachanas, X. Yiakoumis, 2012, Leukemia & lymphoma.

Prognostic significance of deletion of the long arm of chromosome 20 in patients with myelodysplastic syndrome (MDS): a study of the Greek MDS Study Group

E. Terpos, Nikolaos Laoutaris, E. Papadaki, 2006, European journal of haematology.

319 Response to treatment with erythropoietin in patients with MDS highly predicts low risk of evolution to AML and longer survival

E. Terpos, I. Kotsianidis, M. Protopapa, 2011 .

Mutations and Expression of the ras Family Genes in Leukemias

D. Spandidos, M. Ergazaki, H. Kiaris, 1996, Stem cells.

Patterns of bone marrow involvement in chronic lymphocytic leukemia and small lymphocytic (well differentiated) non‐hodgkin's lymphoma. Its clinical significance in relation to their differential diagnosis and prognosis

C. Kittas, G. Pangalis, P. Fessas, 1984, Cancer.

Renal Failure in Multiple Myeloma: Incidence, Correlations and Prognostic Significance.

M. Dimopoulos, E. Kastritis, A. Symeonidis, 2006 .

Treatment of Waldenstrom's Macroglobulinemia with the Combination of Fludarabine and Cyclophosphamide

M. Dimopoulos, C. Papadimitriou, E. Efstathiou, 2003, Leukemia & lymphoma.

Dendritic cells in patients with type I Gaucher disease are decreased in number but functionally normal.

A. Symeonidis, I. Micheva, T. Marinakis, 2006, Blood cells, molecules & diseases.

An improved flow cytometric assay for detection and discrimination between malignant cells and atypical mesothelial cells, in serous cavity effusions

P. Athanassiadou, G. Paterakis, N. Tsagarakis, 2011, Cytometry. Part B, Clinical cytometry.

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma.

M. Dimopoulos, E. Efstathiou, D. Gika, 2004, The hematology journal : the official journal of the European Haematology Association.

Translocation (X;12)(p11;p13) as a sole abnormality in biphenotypic acute leukemia.

G. Paterakis, G. Pantelias, K. Manola, 2007, Cancer genetics and cytogenetics.

Treatment of Waldenstrom's macroglobulinemia with thalidomide.

M. Dimopoulos, N. Viniou, P. Panayiotidis, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of patients with myelodysplastic syndrome with amifostine.

A. Galanopoulos, N. Anagnostopoulos, T. Marinakis, 2001, Leukemia research.

Intravascular B‐cell lymphoma with leukemic presentation: case report and literature review

I. Savvidou, Maria Georgiakaki, Vasilios Xanthopoulos, 2007, European journal of haematology.

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

M. Dimopoulos, T. Economopoulos, E. Kastritis, 2009, Leukemia.

Thalidomide and dexamethasone combination for refractory multiple myeloma.

M. Dimopoulos, K. Zervas, C. Papadimitriou, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

VAD-doxil vs.VAD-doxil Plus Thalidomide as Initial Treatment in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group.

M. Dimopoulos, M. Kyrtsonis, E. Terpos, 2006 .

VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group.

M. Dimopoulos, M. Kyrtsonis, E. Katodritou, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

As white as ivory: sclerotic vertebra in POEMS syndrome

A. Markou, G. Piaditis, K. Liapis, 2017, The Lancet.

Primary Renal Lymphoma Presenting with Chronic Low-Grade Fever

N. Anagnostopoulos, A. Zomas, E. Michalis, 2004, International journal of hematology.

Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.

A. Tsimberidou, G. Paterakis, X. Yataganas, 2002, Leukemia research.

Clozapine-Induced Late Agranulocytosis and Severe Neutropenia Complicated with Streptococcus pneumonia, Venous Thromboembolism, and Allergic Vasculitis in Treatment-Resistant Female Psychosis

C. Voulgari, N. Anagnostopoulos, G. Paterakis, 2015, Case reports in medicine.

Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent

M. Dimopoulos, N. Anagnostopoulos, A. Zomas, 2000, Bone Marrow Transplantation.

Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.

M. Dimopoulos, M. Kyrtsonis, A. Vassou, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years

M. Dimopoulos, K. Konstantopoulos, T. Economopoulos, 2010, American journal of hematology.

Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone.

M. Dimopoulos, D. Margaritis, C. Tsatalas, 2003, Seminars in oncology.

Prognostication of the high-risk WM patient.

M. Dimopoulos, K. Konstantopoulos, T. Economopoulos, 2011, Clinical Lymphoma, Myeloma & Leukemia.

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH).

M. Dimopoulos, E. Kastritis, M. Gavriatopoulou, 2009, Leukemia research.

Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.

M. Dimopoulos, T. Economopoulos, K. Zervas, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of serum beta2-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment.

M. Dimopoulos, M. Kyrtsonis, K. Zervas, 2006, Clinical Lymphoma & Myeloma.

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

M. Dimopoulos, T. Economopoulos, M. Kyrtsonis, 2004 .

Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon‐α with melphalan and prednisone (MP) and interferon‐α (IFN‐α) in patients with good‐prognosis multiple myeloma: a prospective randomized study

M. Dimopoulos, K. Zervas, K. Bourantas, 2001 .

Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.

M. Dimopoulos, K. Zervas, K. Bourantas, 2001, European journal of haematology.

Μultiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia

A. Galanopoulos, M. Georgiakaki, N. Anagnostopoulos, 2009, Annals of Hematology.

M. Dimopoulos, D. Heath, P. Croucher, 2008, Leukemia.

Visual screening for JAK2V617F mutation by a disposable dipstick

Jan Traeger-Synodinos, Theodore K. Christopoulos, T. K. Christopoulos, 2010, Analytical and bioanalytical chemistry.

Treatment o f W aldenstrom's M acroglobulinemi a With T halidomide

M. Dimopoulos, N. Viniou, P. Panayiotidis, 2001 .

Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.

M. Dimopoulos, M. Kyrtsonis, A. Vassou, 2006, Haematologica.

Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors

M. Dimopoulos, E. Kastritis, K. Zervas, 2004, Leukemia & lymphoma.

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.

M. Dimopoulos, E. Kastritis, E. Terpos, 2005 .

Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study.

E. Papageorgiou, E. Bouza, E. Giamarellos‐Bourboulis, 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

M. Dimopoulos, A. Vassou, E. Katodritou, 2004 .

The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function.

M. Dimopoulos, K. Konstantopoulos, T. Economopoulos, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.